Claims for Patent: 6,932,777

Summary for Patent: 6,932,777

Title:	Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
Abstract:	The present invention provides prophylactic and therapeutic methods of treating the ductal epithelium of an exocrine gland, in particular a mammary gland, for disease, in particular cancer. The methods comprise contacting the ductal epithelium of the exocrine gland with an epithelium-destroying gent, preferably by ductal cannulation, so as to realize a prophylactic or therapeutic effect.
Inventor(s):	Sukumar; Saraswati Vaidyanathan (Columbia, MD)
Assignee:	Johns Hopkins University School of Medicine (Baltimore, MD)
Application Number:	09/971,901
Patent Claims:	1. A method of treating the ductal epithelium of a mammary gland therapeutically for cancer, which method consists of contacting, by ductal cannulation, the ductal epithelium of the mammary gland with a composition consisting of one or more cytotoxic compounds selected from the group consisting of genistein, okadaic acid, 1-.beta.-D-arabinofuranosyl-cytosine, arabinofuranosyl-5-aza-cytosine, cisplatin, carboplatin, actinomycin D, asparaginase, bis-chloro-ethyl-nitroso-urea, bleomycin, chlorambucil, cyclohexyl-chloro-ethyl-nitroso-urea, cytosine arabinoside, duanomycin, etoposide, hydroxyurea, melphalan, mercaptopurine, mitomycin C, nitrogen mustard, procarbazine, teniposide, thioguanine, thiotepa, vincristine, 5-flurouracil, 5-fluorocytosine, cyclophosphamide, methotrexate, vinblastine, doxorubicin, leucovorin, taxol, an anti-estrogen agent, an intracellular antibody against an oncogene, a flavonol, Guan-mu-tong extract, a retinoid, an analogue of a retinoid, and a monoterpene to destroy the ductal epithelium so as to inhibit the spread of cancer. 2. The method of claim 1, wherein the one or more cytotoxic compounds is doxorubicin. 3. The method of claim 2, wherein the one or more cytotoxic compounds is 5-fluorouracil. 4. The method of claim 3, wherein the one or more cytotoxic compounds is cyclophosphamide. 5. The method of claim 1, wherein the one or more cytotoxic compounds is 5-fluorouracil. 6. The method of claim 5, wherein the one or more cytotoxic compounds is cyclophosphamide. 7. The method fo claim 1, wherein the one or more cytotoxic compounds is cyclophosphamide. 8. The method of claim 7, wherein the one or more cytotoxic compounds is doxorubicin. 9. A method of treating the ductal epithelium of a mammary gland therapeutically for cancer, which method consists of contacting, by ductal cannulation, the ductal epithelium of the mammary gland with a composition consisting of (i) one or more cytotoxic compounds selected from the group consisting of genistein, okadaic acid, 1-.beta.-D-arabinofuranosyl-cytosine, arabinofuranosyl-5-aza-cytosine, cisplatin, carboplatin, actinomycin D, asparaginase, bis-chloro-ethyl-nitroso-urea, bleomycin, chlorambucil, cyclohexyl-chloro-ethyl-nitroso-urea, cytosine arabinoside, duanomycin, etoposide, hydroxyurea, meiphalan, mercaptopurine, mitomycin C, nitrogen mustard, procarbazine, teniposide, thioguanine, thiotepa, vincristine, 5-flurouracil, 5-fluorocytosine, cyclophosphamide, methotrexate, vinblastine, doxorubicin, leucovorin, taxol, an anti-estrogen agent, an intracellular antibody against an oncogene, a flavonol, Guan-mu-tong extract, a retinoid, an analogue of a retinoid, and a monoterpene and (ii) a cytokine or hematopoietic growth factor to destroy the ductal epithelium so as to inhibit the spread of cancer. 10. The method of claim 9, wherein the one or more cytotoxic compounds is doxorubicin. 11. The method of claim 10, wherein the one or more cytotoxic compounds is 5-fluorouracil. 12. The method of claim 11, wherein the one or more cytotoxic compounds is cyclophosphamide. 13. The method of claim 9, wherein the one or more cytotoxic compounds is 5-fluorouracil. 14. The method of claim 13, wherein the one or more cytotoxic compounds is cyclophosphamide. 15. The method of claim 9, wherein the one or more cytotoxic compounds is cyclophosphamide. 16. The method of claim 15, wherein the one or more cytotoxic compounds is doxorubicin. 17. The method of claim 5, wherein the hematopoietic growth factor is GM-CSF.

Details for Patent 6,932,777

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2015-08-03